Pharming Group (NASDAQ:PHAR) Stock Price Down 4.9% - Should You Sell?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) traded down 4.9% during mid-day trading on Tuesday . The stock traded as low as $10.46 and last traded at $10.47. 33,193 shares traded hands during trading, an increase of 439% from the average session volume of 6,157 shares. The stock had previously closed at $11.00.

Analysts Set New Price Targets

PHAR has been the subject of a number of research reports. Oppenheimer raised their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.

Pharming Group Stock Down 2.5%

The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.76. The stock's 50 day simple moving average is $10.38 and its 200 day simple moving average is $9.41. The firm has a market cap of $706.16 million, a P/E ratio of -51.90 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The business had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.